From Chief Regional Patient Advocate Fiona Wardman The last few months have been busy in the countries in the Asia Pacific region and South Africa. As the 2022 HAEi Global Leadership Workshop invitations have been sent out to the Member Organizations, there has been a lot of interest, and registrations have been completed. I’m [...]
From HAE Australasia HAE Australasia has held two in-person patient and carers meetings in February. The first meeting was held in Sydney, Australia, on 5 February, the main venue with presenters in Sydney. Brisbane and Melbourne were linked via Zoom. Other patients and carers around Australia and New Zealand could dial in to watch [...]
From Chief Regional Patient Advocate Fiona Wardman For the last few months, I have focused on catching up with the Member Organizations in the Asia Pacific region and South Africa via virtual means. It seems that everyone is looking forward to once again being able to meet face-to-face. The latest tools and resources have [...]
From CEO Fiona Wardman, HAE Australasia: Patients in Australia are thankful for our Health Minister’s decision to sign off on the recommendation to fund Takhzyro (lanadelumab). As of 1 December 2021, more patients have access to this treatment, closing the gap of access for prophylaxis medications for many of our patients. Our patients in [...]
From Chief Regional Patient Advocate Fiona Wardman There have been a few focused tasks and projects in the Asia Pacific region over the most recent months, including the rolling out the new member only access courses in Advocacy Academy. During this period, I have attended virtual conferences and symposiums for the region, including the [...]
From CEO Fiona Wardman, HAE Australasia: HAE Australasia is excited that the Pharmaceuticals Benefit Advisory Committee in Australia has recommended lanadelumab be listed on the pharmaceuticals benefits scheme (PBS), making this treatment available to patients in Australia. We look forward to this treatment being officially listed towards the end of the year. HAE Australasia [...]
Happy birthday to HAE Hong Kong! Congratulations to the team at HAE Hong Kong for their 2nd year of dedication to improving the quality of life for patients in Hong Kong. During the last few months, I have participated in meetings with various pharmaceutical companies to move forward access to modern therapies in the [...]
From CEO Fiona Wardman, HAE Australasia: HAE Australasia and its members (in Australia) welcomed the news that subcutaneous C1 is now indicated for children aged eight and older. There have been quite a few questions from HAE patients around receiving the COVID-19 vaccinations. HAE Australasia has made available the information from HAEi on this [...]
Since the last magazine, there has been a focus on a few projects; a couple of these were the hae day :-) “Let’s Take the Next Steps” campaign and rolling out of the Regional Medical Advisory Panel project. All the member organizations within the Asia Pacific region had their history and plans for the [...]
This input is dated May 2021 In brief Name for organization: HAE Australasia (Australia and New Zealand) Patient group started in 2010 – now HAE Australasia (2013) 38 members at 1 Jan 2021 Name of approved HAE treatments: Icatibant – for acute attacks (ages 2 and above) Fun/interesting [...]
HAE International is a global non-profit network of member organizations dedicated to raising awareness of hereditary angioedema and improving the lives of people with HAE.
HAE International (HAEi)
10560 Main Street, Ste PS40
Fairfax City, VA 22030
United States of America
gro.ieah@ofni
HAE International (HAEi)
Vejlevej 16, 1.
8700 Horsens
Denmark
gro.ieah@ofni
